Latest Breaking News On - துறை ஆஃப் மருத்துவ சிகிச்சை - Page 2 : comparemela.com

ABBVie announced today that the U.S. Food and Drug Administration approved the update of the IMBRUVICA ® Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of … – ABBVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA ® (ibrutinib) Prescribing Information to include efficacy and safety data for the combination of IMBRUVICA with rituximab for the treatment of Waldenström’s macroglobulinemia (WM), based on the final analysis of the Phase 3 iNNOVATE study. First approved in 2013, IMBRUVICA is currently available to patients with several types of blood cancer, as well as chronic graft-versus-host disease. It was approved as a monotherapy for WM in 2015 and

Meletiosa dimopoulosDanelle jamesAbbvie companyJanssen biotech incGlobal developmentDrug administrationExchange commissionKapodistrian university of athens school medicineDepartment of clinical therapeuticsLymphoma research foundationNational comprehensive cancer networkPrescribing informationDevelopment leadClinical therapeuticsKapodistrian universityAthens school